rme-2022-0002 Supplementary Figures & Tables.docx
Objective: To evaluate the long-term safety and efficacy of adipose-derived mesenchymal stem cell (ADMSC) therapy in the treatment of knee osteoarthritis (OA).
Methods: 329 participants with knee OA underwent intra-articular ADMSC therapy. Participants were followed up for 24-months and were separated based on radiological OA grade.
Results: Treatment was well tolerated with no related serious adverse events. All participant groups reported clinically and statistically significant pain improvement. Clinical outcome was not influenced by patients’ age or BMI.
Conclusion: ADMSC therapy is a safe and long-lasting effective treatment option for knee OA with the potential to delay total joint replacement. In addition to the observed clinical benefits, ADMSC therapy promises to reduce the global economic burden of OA.
Table 1. Adverse Events associated with abdominal lipoharvest procedure
Table 2. Adverse Events associated with ADMSC therapy
Table 3. Non injection related Adverse Events documented during the 24month period of follow-up
Figure 1. Whole cohort vs. non total joint replacement cohort outcome analysis – NPRS
Figure 2. Whole cohort vs. non total joint replacement cohort outcome analysis – WOMAC
Figure 3. OA compartment outcome analysis - WOMAC
Figure 4. Carrier media outcome analysis - NPRS
Figure 5. Carrier media outcome analysis - WOMAC
Figure 6. Linear regression analysis of BMI vs change in baseline WOMAC
Figure 7. Linear regression analysis of age vs change in baseline WOMAC